Stock PHAR PHARMING GROUP N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Pharming Group N.V. Nasdaq

Equities

PHAR

US71716E1055

Market Closed - Nasdaq
Other stock markets
 21:30:00 14/06/2024 BST 		5-day change 1st Jan Change
8.6 USD +0.04% Intraday chart for Pharming Group N.V. +1.90% -24.76%
05-31 Pharming Group Flags Delay in EU Review of Rare Immunodeficiency Drug MT
05-30 Pharming Group N.V. Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of Apds in the European Union CI

Evolution of the average Target Price on Pharming Group N.V.

Price target over the last 5 years

History of analyst recommendation changes

84efe989766.CvkSGy55jA21TITCExVb0GBuQNJcyJCgFSIKI6lUD4Q.YbJ8KFoB5WeDFLSUWXER4gMGLqAMh9HXTUpPTtgefNRPrnxVfSPTOYwc4w~0b9f33e77380823d0096f13df0e96494

Analyst Recommendations on Pharming Group N.V.

RBC Raises Price Target on Pharming Group to EUR2.10 From EUR1.95, Keeps Outperform Rating MT
Oppenheimer Adjusts Pharming Group Price Target to $40 From $36, Maintains Outperform Rating MT
Oppenheimer Adjusts Pharming Group's Price Target to $36 From $43, Maintains Outperform Rating MT
Van Leeuwenhoeck issues research note on Pharming (PHAR.AS): Turning the Page PU
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.743 EUR
Average target price
1.875 EUR
Spread / Average Target
+152.36%
High Price Target
2.1 EUR
Spread / Highest target
+182.64%
Low Price Target
1.65 EUR
Spread / Lowest Target
+122.07%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Pharming Group N.V.

RBC Capital Markets
Oppenheimer

Ratings for Pharming Group N.V.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. PHARM Stock
  4. PHAR Stock
  5. Consensus Pharming Group N.V.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW